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Simultaneous genotyping of multiple polymorphisms
in human serotonin transporter gene and detection
of novel allelic variants
R Avula, A Rand, JL Black and DJ O’Kane
The serotonin transporter, called SLC6A4, SERT or 5-HTT, modulates neurotransmission by removal of serotonin from the
synapse of serotonergic neurons, facilitating serotonin reuptake into the presynaptic terminus. Selective serotonin reuptake
inhibitors block the action of the serotonin transporter and are used to treat depression and other neuropsychiatric disorders.
Three polymorphisms in the 5-HTT gene have been implicated in treatment response and neuropsychiatric disorders. A 44-bp
promoter ins/del polymorphism (5-HTTLPR) produces primarily long and/or short alleles due to either 14 (short) or 16 (long)
repeats ofvariablyconserved20–23bpunits.Also implicated,a17–18bpvariablenumbertandemrepeatfoundinintron2 (StIn2)
isexpressedastrialleliccontentwith9,10,or12repeats(StIn2.9,StIn2.10orStIn2.12).Finally,asinglenucleotidepolymorphism
rs25531 located within the promoter polymorphic-linked region alters the function of the long promoter allele. We developed a
PCR-based fragment analysis assay, which is analyzed on an ABI sequencer, whereby we are able to detect all three genotypes
simultaneously. Using this technique, we identiﬁed novel sequences, which demonstrate promoter repeat regions containing
(1) a 17 repeat with rs25531 A/G polymorphism, (2) two with 18-repeat units, (3) one with 20-repeat units and (4) a 24-repeat
sequence. The novel repeats were conﬁrmed by direct sequencing of gel-puriﬁed amplicons.
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Introduction
The serotonin transporter in the brain is the principal site of
action for many antidepressant medications in treating major
depressivedisorders.Theserotonintransportergene(5-HTT)
has several polymorphic loci that affect its expression or
function. The promoter polymorphism known as the 5-HTT-
linked polymorphic region (5-HTTLPR) has an ins/del in
the 5-HTTLPR and most commonly is composed of a long
allele (L) or short allele (S) (14 or 16 repeats of the 20–23bp
unit). Variations in the promoter region of 5-HTT have been
reported to be associated with differential remission rates
following selective serotonin reuptake inhibitor medication
treatment.
1,2 The long form of the ins/del promoter variant has
43 or 44 more nucleotides than the short form and has been
shown to drive transcription levels to more than twice the level
of the S allele.
3 In some previous studies, European subjects
homozygous for the L allele of the ins/del promoter variant
have been reported to beneﬁt more from treatment with
medications that block serotonin reuptake than subjects
without the L allele.
1,4 Nakamura et al.,
5 after isolating and
sequencing all the repeat units in the promoter, categorized
four kinds of S allelic variants and six different L allelic
variants, based upon the sequence of the different repeats.
The S alleles were 14-A, 14-B, 14-C, 14-D, and the L alleles
were 16-A, 16-B, 16-C, 16-D, 16-E and 16-F. They also
observed longer repeats composed of 19, 20 and 22 units;
extra long versions of the LPR with 18-, 19- and 20-repeat
units were also reported by others.
6–8 Recently a 17-repeat
allele and an extra short allele of 11 repeats was reported.
8
Hu et al.
3 designated the L allele with an adenosine at single
nucleotidepolymorphism(SNP) rs25531 asLA andtheL allele
with a guanine at rs25531 as LG. The LA and LG designa-
tion corresponds to alleles 16-A and 16-D, respectively, in
Nakamura’s nomenclature. The LA was reported to have
higher activity than LG.
3 The A-G substitution is in the m unit
(sixth unit) and this gave rise to six different genotypes in
the HTTLPR—SS, LGLG,S L G,L ALG,SL A,L ALA, where SS
expressed the least HTT mRNA and LALA expressed the
most, and the two heterozygous genotypes that contain one
copy of the S allele did not exhibit lower than expected
expression as predicted by the S-dominant model.
3 The LG
allele created a stronger AP2-DNA binding site which, in turn,
suppressed transcription. The LA allele was also associated
withhigher5-HTT-bindingpotential,an indexfor5-HTTdensity
in putamen using 3-(11) C-amino-4-(2-dimethylaminomethyl-
phenyl-sulfanyl) benzonitrile ([
11C]DASB) positron emission
tomography.
9 The G substitution is also observed in the
context of S allele (SG), which isvery rare and was designated
as 14-B and 14-D by Nakamura.
5 The ﬁnding that rs25531 is
also associated with selective serotonin reuptake inhibitor
response demand that both 5-HTTLPR and rs25531 be viewed
as two independent loci for genotyping, and demonstrate a
need for more comprehensive genotyping procedures.
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www.nature.com/tpStudies have shownthattheStIn2,another variable number
tandem repeat (VNTR) region, may act as a transcriptional
enhancer of the 5-HTT gene, with 12-repeat allele having
more activity than the 10-repeat allele.
11 The allele frequency
of the 9 repeat is low (1–3% in the European population).
The intronic polymorphism has been mainly investigated in
affective illness. Association of StIn2.9 with unipolar depres-
sionwasshownbyOgilvieetal.
12StIn2.12hasbeenshownto
be associated with bipolar disorder in multiple studies.
6,13,14
Potential association/linkage disequilibrium of the intronic
polymorphism and schizophrenia was also shown.
15
Hranilovic et al.
11 demonstrated the combined effect of
the 5-HTTLPR and StIn2 polymorphism, they separated the
groupsintohigh-expressinggenotypesatbothloci(L/L12/12),
low-expressing genotypes at one locus (L/L 10 and S 12/12)
and those containing low-expressing genotypes (S 10). The
mean 5-HTT expression was the highest with two high-
expressing genotypes, 20% lower with one low-expressing
genotypes and 50% lower with low-expressing genotype
at both the loci. Lovejoy et al.
16 suggested that there is an
additional layer of transcriptional complexity based on the
primary sequence of the VNTR, and that the controversy as to
the correlation of VNTR copy number with predisposition to
affective disorders could be resolved by reanalyzing the data
and taking into account the primary sequence of the VNTR.
The method we developed to genotype 5-HTTLPR, StIn2
and the SNP rs25531 uses ﬂuorescently labeled PCR
primers. An advantage of a ﬂuorescent dye detection system
is that DNA fragments overlapping in size range can be
labeled with different dyes and thus be simultaneously
detected in a single lane or by injection on electrophoresis
instrumentation. Since both the 5-HTTLPR and StIn2 are
composed of repeat regions, there is a possibility of size
overlap. Labelingwith two different dyes providesa signiﬁcant
increase in throughput over the more traditional methods in
detecting the different alleles. Using alternative ﬂuorescent
dyes for the two separate loci, LPR and IN2, along with
designing the products to yield deﬁned and unique fragment
length, enables the amplicons generated in the four separate
PCRs to be separated for the four different reactions in the
same well during electrophoresis. Furthermore the ampliﬁca-
tions were designed to utilize the same cycling conditions to
generate the PCR amplicons. The allele-speciﬁc PCR for the
rs25531 eliminates the restriction enzyme digest of the PCR
amplicon thereby further streamlining the assay and reducing
the chance of errors while lowering the cost of performing the
assay further. Here we present the simultaneous genotyping
of multiple polymorphisms in human serotonin transporter
gene and the novel variants identiﬁed.
Materials and methods
Generating the PCR fragments. Genomic DNA was
extracted using the Qiagen EZ-1 extraction method (Hilden,
Germany). The assay was composed of four separate
ampliﬁcations as follows: amplify the ins/del region of the
promoter using primers 5HTTLPRF and 6FAM5HTTLPRR,
to amplify the StIn2 region with primers 5HTTIN2F and
HEX5HTTIN2R, and two additional reactions to examine the
SNP rs25531 region using two allele speciﬁc primers
5HTTSNPAF and 5HTTSNPGF, with a common reverse
primer 6FAM5HTTLPRR. The promoter region reverse
primer and the StIn2 region reverse primer were
ﬂuorescently labeled with 6FAM and HEX, respectively.
The primer sequences are given in Table 1. In a 12.5-ml
reaction volume, 25ng of genomic DNA were ampliﬁed with
2.5mlo f5  Promega Flexi buffer, 1mlo f2 5m M MgCl2, 0.5ml
of 10mM dNTP mix, 3mlo f5 M betaine (Sigma-Aldrich,
St Louis, MO, USA) and 0.1ml of Promega GoTaq, Hot start
polymerase (Promega Corporation, Madison, WI, USA). The
primers were used at 25mM concentration: 0.5ml was used in
the PCR reaction, except the allele speciﬁc primers, which
were 0.1ml in the reaction. Thermal cycling consisted of 2min
of denaturation at 941C followed by 30 cycles of 941C (30s),
621C (30s) and 721C (60s), and with a ﬁnal extension step
of 10min at 721C.
Detection on ABI 3130xl genetic analyzer. The PCR
products were analyzed on ABI 3130xl Genetic analyzer.
A volume of 1ml of sample (composed by pooling 2ml from
each of the four amplicons) was added to a mix of 0.5mlG S
600Liz size marker (Applied Biosystems, Foster City, CA,
USA) and 9ml of Hi-Di formamide (Applied Biosystems). A
volume of 9ml of the marker mix and 1ml of pooled amplicon
was denatured at 951C for 5min, cooled on an ice-water
slurry for 5min, and subsequently run on the ABI 3130xl
analyzer. The data were analyzed using GeneMarker v1.9
(SoftGenetics, State College, PA, USA).
Sequence conﬁrmation. The samples analyzed by fragment
analysis were veriﬁed by direct DNA sequencing. The primers
used for generating the sequencing amplicons and sequencing
primer details are given in Table 1. The primers used to generate
the amplicons for sequencing have M13 sequences on the 50
end. This simpliﬁes the sequencing by using two common
primers for any number of speciﬁc regions. Direct sequenc-
ing was performed using BigDye terminator v3.1/Sequencing
standard kit (Applied Biosystems) following the manufacturer’s
directions and separating products on an ABI 3130xl.
Table 1 Primers and Primer sequences
Primers Sequence (50–30)
5HTTLPRF TGAATGCCAGCACCTAACCC
FAM5HTTLPRR TTCTGGTGCCACCTAGACGC
5HTTIN2F GGGGTCAGTATCACAGGCTGC
HEX5HTTIN2R TCATGTTCCTAGTCTTACGCCAGTG
5HTTSNPAF TTCACCCCTCGCGGCAT
CCCCCCTGCACCCACA
5HTTSNPGF CGCGGCATCCCCCCTGCACCCACG
5HTTM13(LPR)F GGGTTCCCTAAGGGTTGGAG
GCGTTGCCGCTCTGAATGC
5HTTM13(LPR)R GTGCCAGCAAGATCCAATCTAGA
GAGGGACTGAGCTGGACAACCAC
5HTTIN2M13F GGGTTCCCTAAGGGTTGGAA
ATGTCTGGCGCTTCCCCTAC
5HTTIN2M13R GTGCCAGCAAGATCCAATCTA
GAAAGTCATCATGTTCCTAGTC
M13_seq_F GGGTTCCCTAAGGGTTGGA
M13_seq_R GTGCCAGCAAGATCCAATCTAGA
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(SoftGenetics). The samples heterozygous (L and S) for the
promoter region were complex and difﬁcult to analyze using
the software. To conﬁrm the results we obtained, the
amplicons were separated on a 2% agarose gel, and the
short and the long bands were excised and puriﬁed using
GeneClean (Qbiogene, Solon, OH, USA) before sequencing.
Results
Genotyping by fragment analysis. Since the reverse
primers of the promoter region and the StIn2 region were
ﬂuorescently labeled, we were able to detect the alleles
simultaneously by mixing the PCR products. The different
alleles expected for the promoter region are L (long), S
(short), LA,L G,S A and SG. The StIn2 VNTR alleles would be
StIn2.9, 10, and 12 (9R, 10R and 12R repeats). The
expected peak sizes are shown in Figure 1 and Table 2
(R15, A97, M09 and C126 are DNA from the Coriell
repository, Camden, NJ, USA). The L allele peak was at
450 and the S allele peak was at 406. The LA peak was at
327, and the G allele-speciﬁc primers were made nine bases
shorter than the A allele-speciﬁc primer so the LG peak was
at 318, while the SA peak was at 284 (the SG peak should be
275 bases but we did not ﬁnd any SG peak in any of the
samples reported here). The StIn2 alleles yielded fragments
of 248 (9), 265 (10) and 298 (12). The software was set to
allow a variation of ±3 for the promoter polymorphisms and
±3 for the StIn2. As the reverse primer for the promoter
region (6FAM5HTTLPRR) was the same for the 5-HTTLPR
and the allele-speciﬁc PCR, the change in the size of the L/S
allele(s) found in the variant sequences was also reﬂected
in the A/G fragment.
Identiﬁcation of novel alleles. We detected novel alleles
using the genotyping method we developed. The peak sizes
of the new alleles detected are shown in Figure 2 and
Table 2, and the fragments longer than the L allele were
called extra long (XL). Sample 1 was a heterozygous sample
for the 5-HTTLPR polymorphism with S and SA peaks and an
XL peak and StIn2.9/12 genotype for StIn2. The XL peak was
at 470 instead of 450, which was 20 bases more, and the
XLG was at 338 instead of 318, which was, again, 20 bases
more. This sample also had two additional peaks from
the promoter region at 141 and 163 bases. Samples in
Figures 2b-e were all heterozygous for the promoter ins/del
polymorphism and L peak of all the samples were more
than 450, and we called it short/extra long, designated as
S/XL. As the reverse primer was same for the LPR region
and the A/G SNP, if there was a change in size of the L allele
the same size change was seen in the LA/LG if the insertion
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Figure 1 Electropherogram from ABI 3130xl. 1a was a LA/LA for promoter
and StIn2.10. 1b was a LA/LG and StIn2.12. 1c was a SA/SA and StIn2.12
and 1d was a SA/LA with StIn2.12.
Table 2 Fragment sizes of different alleles detected and genotype calls.
Samples Promotor Intron 2 VNTR Genotype
L S XL SNP A/G StIn2.9 StIn2.10 StIn2.12
SA SG LA LG XLA XLG
C126 450 327 265 LA/LA/StIn2.10
A97 450 327 318 297 LA/LG/StIn2.12
M09 406 284 297 SA/SA/StIn2.12
R15 450 406 284 327 297 LA/SA/StIn2.12
Sample 1 406 470 283 338 248 298 XLG/SA/StIn2.9/StIn2.12
Sample 2 406 494 284 371 298 XLA/SA/StIn2.12
Sample 3 407 492 284 369 298 XLA/SA/StIn2.12
Sample 4 406 537 284 413 297 XLA/SA/StIn2.12
Sample 5 406 623 284 504 265 XLA/SA/StIn2.10
Abbreviation: VNTR, variable number tandem repeat.
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Translational Psychiatrywas after the A/G SNP. Sample 2 had an XL peak at 494
and the XLA peak at 371; sample 3 had the XL at 492 and
XLA peak at 369; sample 4 had an XL peak at 537 and
XLA peak at 413; and sample 5 had an XL peak at 623
(approximate because it was run with 600 base ladder)
and the XLA peak at 504.
Sequence veriﬁcation of the novel alleles. The sequence
data of the novel alleles are given in Supplementary
information. We used the same Greek letter designation
used by Nakamura et al.
5 for the different units.
The genetic architecture for the novel alleles are given
in Figure 3 in comparison with LA and LG. Sample 1 had
the same units as the LG allele (16-D), a, b, g, d, e, m, o,
z, Z, y, i, k, l, m, n, x until k, and instead of l there was
a z followed by two m units instead of one m (boldface in
Figure3);wearecallingtheﬁrstmasm’becausethesequence
had an extra base A at the end. This accounted for the extra
20 or 21 bases making this a 17-repeat unit. The two extra
peaks at 141 and 163 bases were from the m’ and m units at
the end.
Sample 2 and 3 had 18-repeat units. Sample 4 had
20-repeat units; these units were different from the 20-repeat
unit reported before,
5,6 which were a, b, g, d, e, z, Z, z, Z,
z, Z, z, Z, y, i, k, l, m, n, x. In sample 4, the z unit (6th unit)
was followed by o, z, Z, z, o, z, Z; after Z, it had the same
pattern as LA. Sample 5 was the longest one we found, with
24-repeat units (Figure 3).
Discussion
We developed a method for genotyping the following poly-
morphisms in human serotonin transporter: the 5-HTTLPR
polymorphism, the rs25531 SNP in the promoter and the
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Figure 2 This ﬁgure shows the novel variants we found. In (a) the XL peak was at 470 instead of 450 and the XLG was at 338, this sample had 17 repeats for the
5-HTTLPRXLallele.ItwasaStIn2.9/2.12.(b)HadanXLpeakat494andtheXLApeakwasat371,theXLallelehad18repeatsandthissamplehadStIn2.12repeats.(c)Had
an XL peak at 492 and XLA peak at 369, which was also an 18 repeat, this sample was StIn2.12. (d) Showed an XL peak at 537 and XLA peak at 413, the XL allele was a
20-repeat unit and StIn2.12. (e) Showed an XL peak at 623 (approximate sizing because it was outside the ladder) and a XLA peak at 504, this was a 24-repeat unit and
StIn2.10. All the ﬁve above samples were heterozygous for 5-HTTLPR and showed both S and SA peak.
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under the same cycling conditions, and the polymorphisms
were detected simultaneously in a single electrophoretic step.
This method eliminates time-consuming enzyme digestions
and labor-intensive detection methods like running gels, and
is more appropriate for a clinical setting. The analysis and
interpretation is easy, and the entire assay is more cost-
effective. This method will be validated for routine clinical
testing.
We identiﬁed novel variants in 5-HTTLPR using the method
we developed, and the new variants were veriﬁed by direct
DNA sequencing. We reported for the ﬁrst time a 17-repeat
allele (XL) with the SNP rs25531. This allele had the same
units as LG until the k unit and differed by having a z instead of
l followed by m’ and m units. The m’ unit had the nucleotide A at
the end of the sequence. Typically the only unit that has an A
at the end is the l unit, which was missing at this position;
therefore,thisnewrepeatsequencemustbearecombinantof
m and l. The 17 repeat reported recently had a tandem
duplication of a single k unit.
8 The m, which is the fourteenth
unitin LG(16D), is notusually picked upbythe assaybecause
the unit before that is l, and the primer only anneals in this
region weakly, whereas in this particular sample, as the unit
before the m’ was z, the primer bound strongly and was
detected.
The other four alleles we identiﬁed, the two 18 repeats, the
20 repeat and the 24 repeat followed the similar pattern,
where the repeat elements were inserted after the z unit of LA
(seventh unit). Of the two 18 repeats we detected, one had
alternating units of o and z from repeat 7 to 10, which was
identical to the one reported by Michaelovsky.
7 The other 18
repeat had alternating units of Z and z from 7 to 10 repeat (the
tandem repeats are shown in boldface in Figure 3), repeats 1
to 6 and 11 to18 were same in both alleles.
The 20-repeat allele we found had different units from
the ones reported by Kunugi
6 and Nakamura
5 (boldface
units in Figure 3) from repeat 7 to 11. The 24-repeat
allele had alternating units of o and z from 7 to 10 repeat;
units 11 to 16 and units 17 to 23 were in tandem repeat.
The two m units (sixteenth and twenty-second unit) in the
24-repeat allele were not picked up by the assay as it was
preceded by l units.
All the rare alleles we found were heterozygous samples
with the S allele and XL allele as reported before.
6 All the
repeat insertions occurred after the z unit and seemed to
be the hot spot for recombination. Also, the recombination
region in all the variants were followed by the Z unit, and
sometimes the Z unit is inserted repeatedly; this aligns
with Heils et al.’s
17 suggestion that presence of a sequence
of ‘hot spot’ for deletion mutagenesis (TGCAGCC) is in the
Z repeat element.
The 5-HTTLPR region is highly polymorphic, and repeats
up to 24 units do exist in humans and are found to be
a common occurrence in non-human primates.
18 Presence
of 5-HTTLPR in humans and simians but not in other
mammals like mice may be related to anxiety-related
personality traits so common in humans.
18 The allelic
distribution of the 5-HTT gene has remarkable ethnic
variation, and the XL alleles seem to be largely present in
the African or African-American population. Studies showed
that L and XL alleles were more frequently found in the
Japanese population in sudden infant death syndrome
victims, chronic fatigue syndrome and temporomandibular
disorder,
19–21 whereas Haas et al.
22 were not able to replicate
the association between 5-HTT and sudden infant death
syndrome in the Caucasian population. A large Taiwanese
population displayed a much higher frequency of XL alleles
than other studies, challenging the contention that the XL
alleles are rare.
23 As the L allele shows more efﬁcient
serotonin function than the S allele, this raises the question
of whether the XL allele would exhibit even greater resilience
to depression than the L allele.
23
Very few functional studies have been reported on these
rare alleles. It is well established that the L allele is associated
with better and faster response to selective serotonin
reuptake inhibitor therapy. Smeraldi et al.
24 found signiﬁcant
differences in response to ﬂuvoxamine among carriers of
different alleles identiﬁed by Nakamura et al.
5 They found that
carriersof16-Fshowedonlyapartialresponse,whereas16-D
showedamarginallybetterresponsethan16-Aallele carriers.
The authors attribute this difference to the interaction of
various transcription factors with the different consensus
regions.
24 A similar observation was made where transcrip-
tion factors YB-1 (Y box-binding protein) and CTCF (CCTC-
binding factor) have an important role in the regulation of the
StIn2 polymorphism.
25 Ehli et al.
8 showed that there was no
signiﬁcant differencein expressionbetween theextra short11
repeat, and the S, and LG alleles, and a slight decrease of
expression with the 17-repeat allele compared with LA. It will
be interesting to see if there is any difference in expression
with the SNP rs25531 in the 17 repeat.
Serotonin uptake is genetically controlled, and dysregula-
tion of 5-HTT function has been reported in various complex
behavioral traits and disorders such as depression, bipolar
disorder, anxiety, obsessive-compulsive disorder, schizo-
phrenic and neurodegenerative disorders, substance abuse
and eating disorders.
26–31 5-HTT is the main target for
widely used antidepressants, so it will be beneﬁcial in the
future to study the signiﬁcance of these XL and other rare
Figure 3 5-HTTLPR novel variants and the different units identiﬁed (the unique
units are shown in boldface or within brackets).
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inhibitor therapeutics.
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